logo
Plus   Neg
Share
Email

Genentech Reports Positive Topline Data From Xolair Phase III Studies

Genentech, a member of the Roche Group (RHHBY), said Omalizumab has met both co-primary endpoints and key secondary endpoints across both POLYP 1 and POLYP 2 phase III trials for the treatment of adults with chronic rhinosinusitis with nasal polyps (CRSwNP) who have not adequately responded to intranasal corticosteroids. Xolair (Omalizumab) significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps in both studies. Xolair was well tolerated and the safety profile was consistent with the previous trials.

In the US., Novartis and Genentech, Inc. jointly develop and co-promote Xolair. Outside the US, Novartis markets Xolair and records its sales. The companies plan to discuss the results with the FDA.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Canada's new regulations that provide extra protection for airline passengers will kick in Monday, July 15. The new rules from the Canada Transportation Agency, which has received severe backlash from industry and consumer advocates, requires airlines to compensate passengers up to $2,400 if they... California-based Fieldsource Food Systems Inc. has recalled about 13,000 pounds of diced beef and chicken products due to misbranding and undeclared allergens. The company says the product contain wheat, a known allergen, but is not declared on the product label. The uncooked, marinated, diced beef... The U.S. may approve certain companies to re-start new sales to Chinese telecom equipment giant Huawei in as soon as two weeks, Reuters reported Sunday, citing a senior U.S. official. According to the report, licenses will be issued to the U.S. companies on a case-by-case basis, starting in the next two to four week. Huawei is the world's largest telecom equipment maker.
Follow RTT